Winner F A Plus Injection
Glucose Monohydrate 9.138g · L-Isoleucine 0.38g +24 more
Solution · Prescription medication · Combination
JW Pharmaceutical Corp.
MFDS item code 202301977 · Approved 2023.06.28 · Insurance code 678901321,678901322
Correction of nutritional deficiencies (amino acids, calories, fatty acids, etc.) and fluid and electrolyte deficiencies
This medicine is used for patients who are unable to receive oral intake or adequate nutrition through the gastrointestinal tract. It improves the nutritional status by supplying required fluids, electrolytes, amino acids, calories, essential fatty acids, and Omega-3 fatty acids via intravenous route. This helps maintain the body's nutritional balance and assists recovery, effectively providing essential nutrients even when proper nutritional management is difficult. Thus, this medicine plays a crucial role in improving limited nutritional intake conditions.
The dose and infusion rate are determined according to the patient's ability to eliminate fat and metabolize nitrogen and glucose, and nutritional requirements. The dose and bag size are determined based on the patient's condition and body weight. Trace elements, vitamins, electrolytes, etc., may be added depending on the patient's condition. - Patients with normal nutritional status or mild metabolic stress: nitrogen 0.10-0.15 g/kg/day (amino acids 0.6-0.9 g/kg) - Patients with moderate to high metabolic stress, regardless of nutritional status: nitrogen 0.15-0.25 g/kg/day (amino acids 0.9-1.6 g/kg) In very special cases (e.g., burns or marked anabolic states), the amount of nitrogen may be higher. Dose A daily dose of 13-33 mL/kg of this medicine corresponds to nitrogen 0.137-0.347 g/kg and total energy 11.986-30.426 kcal/kg (non-protein energy 8.684-22.044 kcal/kg). This meets the requirements of most patients. In obese patients, the dose should be based on predicted normal body weight. Infusion rate The infusion rate should not exceed 1.5 mL/kg per hour (corresponding to glucose 0.125 g/kg, amino acids 0.095 g/kg, and fat 0.053 g/kg). The recommended infusion duration is 14-24 hours. Maximum daily dose The maximum daily dose depends on the patient's clinical condition and may vary from day to day. The recommended maximum daily dose is 33mL/kg. The recommended maximum daily dose of 33 mL/kg provides nitrogen 0.347 g/kg (amino acids 2.096 g/kg), glucose 2.746 g/kg, fat 1.168 g/kg, and total energy 30.426 kcal/kg (equivalent to non-protein energy 22.044 kcal/kg). Administer by intravenous infusion through a central vein.
Use in children is not recommended.
This drug must be used according to the doctor's instructions, and if allergic reactions such as fever, chills, rash, or difficulty breathing occur during use, administration must be stopped immediately. Moreover, using this medicine with certain calcium-containing intravenous preparations or ceftriaxone can result in precipitation, so they should not be administered simultaneously using the same infusion device. It should be used cautiously in premature or low-birth-weight infants, as administration in premature infants with serious respiratory conditions has been reported to pose a risk of death. Patients with allergies to fish, eggs, soybeans, peanuts, or who have severe hyperlipidemia, liver dysfunction, blood coagulation disorders, severe kidney failure, acute shock, or uncontrolled hyperglycemia should not use this medication. Patients with renal failure, diabetes, liver dysfunction, sepsis, or any condition affecting fat metabolism should be cautious during administration. This medicine can cause side effects like fever, generalized edema, nausea, constipation, dizziness, delirium, nausea, vomiting, chills, sweating, increased body temperature, and hyperglycemia; serious conditions like lipid overload syndrome may occur, so administration should be discontinued if symptoms appear. If an excess of amino acids or dextrose is administered, side effects such as nausea, vomiting, or hyperglycemia may occur, so recommended doses and rates should be strictly adhered to. During the initial administration, the patient's condition should be closely monitored, and administration should start after electrolyte and fluid balance has been improved. The risk of infection is higher when administered via central venous access, so aseptic procedures must be strictly followed, and regular monitoring of blood lipid levels and other clinical indicators should be conducted to detect any abnormal signs early. If this medication is used for an extended period, there should be management of nutritional status considering increased excretion of trace elements, and it should not be administered simultaneously with blood. In patients with renal failure, phosphate and potassium intake should be controlled to prevent hyperphosphatemia and hyperkalemia, and electrolyte dosages should be adjusted based on the patient’s condition. In patients with poor nutritional status, fluid shifts can lead to pulmonary edema or heart failure, making careful observation and adjustment necessary during administration. The safety in pregnant and nursing women has not been established, thus it should only be used when the therapeutic benefits outweigh the potential risks. In cases of overdose, the infusion rate should be slowed or stopped, and appropriate treatments such as insulin administration or hemodialysis should be implemented if necessary. This medicine should be stored at 1-30°C, kept sealed to prevent air exposure, and used immediately after mixing; if not, it should be used within 24 hours at 2-8°C.
fever, chills, rash, shortness of breath, fever, generalized edema, nausea, constipation, decreased blood counts, dizziness, delirium, syndrome of inappropriate secretion of antidiuretic hormone, hyperlipidemia, fever, fatty infiltration, jaundice, hepatomegaly, splenomegaly, anemia, leukopenia, thrombocytopenia, coagulopathy, hemolysis, reticulocytosis, abnormal liver function test results, coma, vomiting, chills, sweating, elevated body temperature, hyperglycemia, allergic reactions
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a sealed container to protect it from air exposure, ideally kept at room temperature between 1°C and 30°C. Storing it this way maintains its efficacy and prevents deterioration.
This medicine consists of three compartments separated by an interior white and external packaging, with oxygen absorber pouches in between. Each compartment contains a dextrose solution, an amino acid and electrolyte solution, and
1085mL (A solution 215mL, B solution 689mL, C solution 181mL) / bag, 1090mL (A solution 216mL, B solution 692mL, C solution 182mL) / bag, 1438mL (A solution 285mL, B solution 913mL, C solution 240mL) / bag, 1820mL (A solution 360mL, B solution 1156mL, C solution 304mL) / bag
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Glucose Monohydrate 9.138g · L-Isoleucine 0.38g +24 more
Solution · Prescription medication · Combination
JW Pharmaceutical Corp.
Glucose Monohydrate 462g · L-Isoleucine 6g +24 more
Solution · Prescription medication · Combination
JW Pharmaceutical Co., Ltd.
Glucose Monohydrate 143g · L-Isoleucine 6g +24 more
Solution · Prescription medication · Combination
JW Life Science Co., Ltd.
L-Isoleucine 0.22g · Glucose Monohydrate 7.08g +24 more
Solution · Prescription medication · Combination
JW Life Science Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.